18F-FDGal PET/CT and PET/MRI in Patients With Hepatocellular Carcinoma
NCT ID: NCT05871892
Last Updated: 2024-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
125 participants
INTERVENTIONAL
2023-09-11
2027-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Extrahepatic spread of HCC is common at advanced stages with haematogenous spread to lungs, bones and adrenal glands or lymphatic spread to regional lymph nodes.
The majority of patients who develop HCC have cirrhosis of the liver and in these patients, diagnosis can be made non-invasively with characteristic contrast-enhancement pattern on computed tomography (CT) and/or magnetic resonance imaging (MRI). Although contrast-enhanced CT and MRI are considered equal in current guidelines, MRI may have a better sensitivity especially for small lesions.
Positron emission tomography (PET) is a molecular imaging technique based on the injection of a very small dose of a tracer substance labelled with a positron emitting radioisotope. PET with the glucose tracer 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (18F-FDG) is an important tool in the staging of many cancer forms, but it is not included in the international guidelines for management of HCC because of suboptimal sensitivity of only up to 50-60 % for HCC situated in the liver.
In Aarhus, the liver specific tracer 18F-FDGal has been developed. It is a fluorine-18 labelled galactose analogue which in the human body is trapped in hepatocytes by phosphorylation by galactokinase. The first study of the diagnostic use of 18F-FDGal PET/CT in patients suspected of having HCC was published in 2011. The study showed good clinical potential for 18F-FDGal as a tracer for detection of intra- as well as extrahepatic HCC.
The aim of the present project is to establish the clinical impact and utilization of 18F-FDGal PET/CT and PET/MRI in patients suspected of having HCC or diagnosed with HCC, for staging and evaluation of treatment response including effect of treatment on liver function.
Hypotheses:
I. Adding 18F-FDGal PET/CT or PET/MRI to diagnostic work-up of patients suspected of or diagnosed with HCC will add to the establishment of a definitive diagnosis and improve staging and thus choice of treatment.
II. The uptake pattern of 18F-FDGal in HCC provides prognostic information and can be used to evaluate regional metabolic liver function before and after loco-regional treatment.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
18F-FDGal PET/CT or PET/MRI
Diagnostic scan.
18F-FDGal PET/CT or PET/MRI
All patients suspected of or diagnosed with HCC will be offered an initial 18F-FDGal PET/CT or PET/MRI scan. Moreover, patients who undergo loco-regional treatment (resection, ablation (radiation or microwave), chemo- or radio-embolization) are re-examined with 18F-FDGal. The scans will be performed 1-2 months and 3-5 months after the loco-regional treatment. The images will be analyzed by an experienced PET specialist and the CT or MR images by an experienced radiologist for focal lesions and compared to other imaging modalities. The investigators expect approximately 25 patients per year during a 5-year period and as such aim at a total of 125 patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18F-FDGal PET/CT or PET/MRI
All patients suspected of or diagnosed with HCC will be offered an initial 18F-FDGal PET/CT or PET/MRI scan. Moreover, patients who undergo loco-regional treatment (resection, ablation (radiation or microwave), chemo- or radio-embolization) are re-examined with 18F-FDGal. The scans will be performed 1-2 months and 3-5 months after the loco-regional treatment. The images will be analyzed by an experienced PET specialist and the CT or MR images by an experienced radiologist for focal lesions and compared to other imaging modalities. The investigators expect approximately 25 patients per year during a 5-year period and as such aim at a total of 125 patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age above 18 years
Exclusion Criteria
* The responsible investigator determines that the patient is not qualified for a PET scan.
* Patients who are offered systemic chemotherapy or best supportive care will be excluded.
* Renal insufficiency (estimated glomerular filtration rate \[eGFR\] \<30 ml/min/1.73 m2 body surface area).
* Pregnant or nursing patients.
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mona Kristiansen, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1-10-72-71-22
Identifier Type: -
Identifier Source: org_study_id